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Mediated FoxP3+ Regulatory T Cells
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Gyongyi Szabo*
Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
Abstract
Background & Aims: Hepatitis C virus (HCV) is difficult to eradicate and type III interferons (IFN-l, composed of IL-28A, IL-
28B and IL-29) are novel therapeutic candidates. We hypothesized that IFN-l have immunomodulatory effects in HCV-
infected individuals.
Materials and Methods: We analyzed the expression of IFN-l and its receptor (composed of IL-10R2 and IFN-lR subunits) in
the blood and livers of patients with chronic (c)HCV infection compared to controls (those who cleared HCV by sustained
virological response, SVR, and those with liver inflammation of non-viral origin, non-alcoholic steatohepatitis, NASH). We
also compared the proliferative capacity of dendritic cells (DCs) obtained from healthy individuals and those with chronic
HCV using a mixed leukocyte reaction combined with 3H-Td incorporation. In addition, the composition of the IFN-l
receptor (IFN-lR) on myeloid DCs, plasmacytoid DCs, PBMCs, and T cells was determined by FACS analysis.
Results: We report that the expression of IFN-l protein in serum and mRNA in liver is increased in cHCV patients, but not in
those with HCV SVR or NASH, compared to controls. Liver level of IFN-lR mirrored the expression of serum IFN-l and was
higher in cHCV, compared to controls and HCV-SVR patients, suggesting that elevation of IFN-l and IFN-lR are HCV-
dependent. We further identified that innate immune cell populations expressed complete IFN-l receptor. In vitro,
recombinant IFN-l promoted differentiation of monocyte-derived dendritic cells (DCs) into a phenotype with low T cell
stimulatory capacity and high PD-L1 expression, which further promoted expansion of existing regulatory T cells. IFN-l-DCs
failed to induce de novo generation of regulatory T cells. The inhibitory capacity of IFN-l-DCs was counteracted by
recombinant IL-12 and by neutralization of the PD-1/PD-L1 system.
Conclusions: Our novel findings of the immunomodulatory effect of IFN-l contribute to the understanding of the anti-
inflammatory and/or anti-viral potential of IFN-l in cHCV.
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Introduction
Chronic infection with Hepatitis C virus (cHCV) is present in
3% of the world’s population with prevalence ranging from 0.1–
5% in different European countries [1]. HCV is currently treated
with a combination of interferon alpha and ribavirin, however a
sustained virological response (SVR) is achieved only in ,50% of
cases [1,2]. More recently IFN-lambda (IFN-l) has emerged as a
potential new therapeutic option for HCV infection. Elevated
IFN- l transcripts were identified in the livers and in the
peripheral blood mononuclear cells (PBMCs) of patients with
cHCV [3,4]. In vitro IFN- l is a potent inhibitor of HCV
replication [4,5]. Preclinical and early clinical data indicated that
IFN- l was well tolerated in animals and presented minimal side
effects. [6]. Further, genetic variations in IFN- l genes may predict
sustained virological response (SVR) to standard therapy [7].
The IFN- l class includes 3 cytokines, IL-29 (IFN- l 1), IL-28A
(IFN- l 2), and IL-28B (IFN- l3), which are produced upon
stimulation with viruses or certain Toll-like receptor ligands mostly
by hepatocytes, epithelial cells, and to a lesser extent by immune
cells [5,8,9]. All IFN- l class cytokines employ a common IFN- l
heterodimer receptor composed of a unique IFN- l R1 chain and
an IL-10R2 chain, the latter is also used by other cytokine
receptors [8]. The signaling events downstream of IFN- l R are
shared with IFN-aR and include activation of STAT1, STAT2,
and IRF9, all leading to induction of interferon-stimulated genes
and antiviral activity. Taking into account that IFN- l polymor-
phisms are associated with both treatment-induced and with
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natural HCV SVR [7,10], it is likely that in vivo IFN- l may be
involved in anti-HCV innate immunity.
Innate immunity is key to antiviral defense. Innate immune
defects have been identified in cHCV, including relative deficiency
of circulating plasmacytoid dendritic cells (pDCs), altered expres-
sion of pathogen-recognition receptors, and a skewed monocytes/
DC cytokine profile towards enriched production of immunoreg-
ulatory cytokines and impaired production of IFNs (reviewed in
[11]), all leading to an inefficient T lymphocyte response and
persistent cHCV. Regulatory T cells (Tregs) are specialized to
suppress immune activation that are critical in the development of
chronic viral infection and are phenotypically defined as naturally
occurring, CD4+CD25+Foxp3+ or inducible Tregs. We and
others have reported that cHCV is associated with an expanded
Tregs population, both in peripheral blood and liver [12–14].
Treg functions in cHCV could be beneficial, by limiting
inflammation and fibrosis (via direct contact with activated T
cells and/or regulatory cytokines IL-10 and/or TGF-b, or
detrimental, by creating a tolerant environment that favors tumor
growth (reviewed in [15]). To date the mechanism of expansion
and the role of Tregs in cHCV are not fully understood.
Here we report that IFN- l levels in blood and liver are
increased in cHCV. Further, we identified that IFN- l enables
generation of DC populations with regulatory capacity, which
facilitates expansion of Foxp3+Tregs. These results suggest a novel
role of IFN- l in innate anti-HCV immunity.
Materials and Methods
Reagents
Recombinant cytokines IL-2, IL-4, GM-CSF and IFNs (IL-29
and IL-28A) were from Peprotech (Rocky Hill, NJ), anti-IL-10
antibodies (clone JES3-9D7) from Biosource, anti-PD-1 antibody
from eBioscience (San Diego, CA), carboxyfluorescein-succinimi-
dylester (CFSE) was from Invitrogen (Carlsbad, CA), and 3H-
thymidine was from PerkinElmer (Waltham, MA).
Blood Donors and Cell Culture
The study was approved by the Committee for Protection of
Human Subjects in Research at University of Massachusetts
Medical School and all individuals provided written consent to
participate. Patients’ characteristics are described in Table 1. Core
liver biopsies from patients were collected in our clinic and snap-
frozen until analysis. Liver RNA from control individuals (free of
liver disease) was purchased from Origene (n = 3) and from
Stratagene (n = 1). Blood plasma was separated by centrifugation;
PBMC were separated by centrifugation in Ficoll gradient;
monocytes were isolated by adherence to plastic, as previously
described [1]. Serum and cells were paired in controls; liver tissue
was not paired with serum or cells in controls due to the
commercial origin of normal liver RNA. When possible, paired
serum/liver samples were analyzed in HCV and SVR patients.
To test the effect on DC generation, the IFN l (IL-29, IL-28A
or their mixture) was added to adherent monocytes together with
IL-4 and GM-CSF for 7 days. CD4+CD25+ (regulatory) T cells,
CD4+CD252 (effector) T cells, CD16+CD56+ NK cells, BDCA-1+
myeloid dendritic cells, CD123+BDCA-2+ plasmacytoid dendritic
cells, and total CD4+ T cells were purified using magnetic beads
(Miltenyi Biotech and StemCell Technologies), following the
manufacturer’s instructions.
Dendritic Cells and T Cells Function Assay
The T cell-stimulatory capacity of DCs was tested based on the
principles of mixed lymphocyte reaction (MLR) as previously
described [12] with slight modifications. Briefly, DCs were
incubated with total CD4+ T cells in 96-well culture plates. On
day four, 50% of culture supernatant was removed and subjected
to cytokine quantification; the 3H-Td incorporation was evaluated
using a beta-counter at the end of the final 16 h of the 5-day MLR
and T cell proliferation was expressed as counts per minute (cpm).
Alternatively, T cells were labeled with CFSE (10 mM), included
into co-culture assay, recovered on day 10 and subjected to flow
cytometry analysis or RNA extraction. For quantification of
proliferation, CD4+ T cells were recovered from dendritic cell/
Tcells co-culture, stained as detailed in the legends and analyzed
for CFSE fluorescence by flow cytometry. For FoxP3 detection the
cells were permeabelized using PermWash kit (BD Bioscience)
prior to staining. After incubation with the antibodies the cells
were washed, fixed with 1% paraformaldehyde in saline and
analyzed by flow cytometry. Cells were gated based on their size
and granularity and analyzed for fluorescence; data were
expressed as histograms or dot blots.
To identify the inhibitory capacity of dendritic cell-expanded
Tregs, the T cells were included into 2 rounds of MLR. The first
MLR was set up as described above with CD4+ T cells as
responders and control or IFN- l -exposed DCs as stimulators. At
the end of this first MLR, the T cells were recovered, washed,
purified into CD4+CD252 and CD4+CD25+ populations using
magnetic beads, mixed at the indicated ratios and included into a
second round MLR with allogeneic normal dendritic cells.
Proliferation during the second MLR was assessed by incorpora-
Table 1. Clinical characteristics of study individuals.
Parameter Value
Treatment-naı¨ve SVR NASH
Age (years) 42612 48611 4165
Male 20 17 6
Female 4 4 6
AST (U/l) 71623 22611 69631




Fibrosis 8 4 1
Stage 1–2 6 4 1
Stage 3–4 2 0 0
Liver inflammation 22 16 12
Score: 0–6 16 10 9
Score: 7–12 6 6 3
A total of 24 HCV, 21 SVR, 20 controls (serum and/or cells), 4 control liver RNA
and 12 NASH serum were analyzed in our manuscript as follows:
N 18 HCV and 16 SVR pairs of blood and liver were analyzed for the data shown
in Fig. 1.
N 12 control serum and 4 control liver mRNA were analyzed for the data shown
in Fig. 1; these samples were not paired.
N 12 NASH blood (serum) were analyzed for the data shown in Fig. 1.
N The cells from the same 18 HCV analyzed in Fig. 1 were analyzed in Fig. 3 for
their DC allostimulatory capacity.
N Additional 6 HCV, 5 SVR and 8 controls were recruited to perform the
experiments shown in Fig. 3 in order to collect data for achieving sufficient
statistical analysis power.
N Control liver RNA was of commercial origin from individuals without known
liver diseases.
doi:10.1371/journal.pone.0044915.t001
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Figure 1. HCV infection correlates with high levels of IFN-l and IFN-lR. Serum (A,B) and liver levels (C–E) of IL-28 (A-protein; C-mRNA), IL-29
(B-protein, D-mRNA), and IFN-lR (E, mRNA). There were 18 patients with chronic HCV infection, 12 controls, 16 HCV SVR and 12 NASH analyzed for
serum cytokines (panels A,B). There were 18 patients with chronic HCV infection, 4 controls, and 16 SVR analyzed for RNA (panels C–E). The samples
IL-28 and IL-29 Modulate Dendritic Cells
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tion of the 3H-Td incorporation during final 16 h of the 5-day co-
culture.
Cytokines were quantified using specific ELISA kits, following the
manufacturer’s instructions. IL-2, IL-12, and IL-10 kits were from
BD Bioscience, IFN- l 1 (IL-29) and IFN- l 2 (IL-28A, cross-
reacting with IL-28B) were from R&D Systems.
RNA Analysis
Tissue or cell RNA was isolated with RNeasy Kit (Qiagen) and
transcribed to cDNA with FirstStrand cDNA Synthesis Kit
(Promega). Specific primers (all from IDT except 18S (Ambion))
and dsDNA-binding SYBR Green were used to quantify the gene
products using iCycler software and comparative DCt method, as
previously described [1]. The primers sequences were designed
using http://frodo.wi.mit.edu/primer3/tool based on sequences
identified in NCBI nucleotides database; primer sequences are
shown in Table S1. The amplification efficiencies of the targets
and the reference samples were within close range. The
quantification of PCR data was achieved using the comparative
Ct method. We calculated the 2
–DDCt, where DDCt =DCt sample
(patient or experimental group) 2 DCt reference (control). The DCT,sample was
calculated as Ct value for any sample normalized to the
endogenous housekeeping gene and DCt, reference was the Ct value
for the calibrator (normal control) also normalized to the
endogenous housekeeping gene. The mean value of 2–DDCt from
control group was considered equal to 1; the fold change over the
mean 2–DDCt of controls was calculated for all samples by division.
Data were expressed as mean+/2 SD of fold change in every
experimental group compared to control; this method of analysis is
widely accepted in current literature.
The liver RNA of controls (n = 4) was purchased from Origene
and Stratagene; according to the provider the donors were healthy
and did not have liver diseases. This source of normal liver RNA
was used previously by us [16] and others (European Patent
EP1494031) due to worldwide restricted access to normal liver
tissue. Further, we did not use peri-tumoral liver tissue as a control
due to potential implications of IFN- l in tumorigenesis, as
recently described by Yang L et al [17]. We had four samples of
normal liver; these samples were very close in their levels of all
analyzed markers (Fig. 1). Further, these normal liver samples
were run side-by-side with patient samples every time a PCR
analysis was performed to provide a reliable inter-experimental
control.
Fluorescent Antibodies for FACS Analyses
Anti-human Lineage-1 FITC, anti-human HLA-DR PerCp,
anti-human BDCA1 APC, anti-human CD123 PE-Cy7, anti-
human CD56 APC, anti-human CD3 PerCp, anti-human CD4
PE-Cy7, anti-human CD25 APC-Cy7 and anti-human IL-28Ra
were purchased from Biolegend (USA). Anti-human IL-10Rb PE
was purchased from Abcam (UK).
Statistical Analysis
The Wilcoxon analysis in the Statview (SAS Institute) program
was employed for cytokines and mRNA quantification. For flow
cytometry analysis, the statistical parameters from the FlowJo and
CellQuest programs were employed. P values ,0.05 were
considered significant.
Results
IFN- l and IFN- l R Levels are Increased in Patients with
Chronic HCV Infection, but not in those who Achieved
SVR or in Liver Inflammation of Non-viral Etiology
In order to dissect the role of cHCV-induced inflammation in
type III IFN production, we examined IFN-l levels from the blood
and livers of cHCV patients and control patients (Table 1). Serum
IL-28A (Fig. 1A) and IL-29 (Fig. 1B) levels were elevated in
patients with cHCV compared to controls. We also identified
elevated liver mRNA levels of IL-28 (Fig. 1C) and IL-29 (Fig. 1D)
in patients with cHCV compared to controls, which mirrored the
increased serum levels of IFN-l (Fig. 1A,B). cHCV is associated
with chronic inflammation in the liver, which could be due to both
the virus and immune-mediated reaction to the virus. We thus
recruited 2 additional cohorts of patients: those who achieved
sustained viral response (SVR) after treatment and those with non-
alcoholic steatohepatitis (NASH); the former exhibited liver
inflammation of non-viral origin (Table 1). Serum protein
(Fig. 1A,B) and liver RNA (Fig. 1C,D) IFN- l levels of SVR and
NASH patients were comparable to controls and significantly
lower compared to the cHCV cohort. Liver IFN- lR mRNA
mirrored the serum IFN- l levels and was elevated in the cHCV
group compared to control and SVR groups (Fig. 1E). These data
suggested that viral presence was needed to trigger/maintain the
elevated IFN- l levels during cHCV.
IFN- lR is Expressed Differentially among Immune Cells
Close interactions between immune cells and HCV-infected
hepatocytes occur in the liver. Having identified that IFN- l and
IFN- lR are elevated in the livers of cHCV patients (Fig. 1A–E),
we sought to determine the composition of IFN- lR on immune
cells. FACS analysis revealed significant expression of IFN- lR on
BDCA-1+ myeloid dendritic cells (DC), CD123+BDCA-2+ plas-
macytoid DCs, and PBMCs and to a lesser extent on CD4+CD25+
(regulatory) T cells, CD4+CD252 (effector) T cells, and non-CD4+
T cells (Fig. 1F). The IFN- l receptor has 2 components: a unique
IFN- lR1 chain and an IL-10R2 which is shared with other
receptors [8]. FACS analyses revealed IL-10R2 expression in the
individual immune cell populations (data not shown). At the RNA
level, both IFN- lR1 chain and IL-10R2 components of IFN- lR
were characteristic for innate immune cells, including DCs (Fig.
S1), which we subsequently targeted for further investigation. We
also noted similar levels of expression of many of the analyzed
markers in the analyzed cell types when compared between
controls and HCV patients (Fig. S2A), except for higher FoxP3
and lower BDCA-2 levels in PBMCs in cHCV patients compared
to controls (Fig. S2B); this observation was in agreement with
previous reports of increased frequency of Tregs and decreased
numbers of pDCs in blood of HCV patients [12,15,18].
IFN-l Facilitates the Differentiation of DCs with Inhibitory
Capacity
Dendritic cells play a central role in the innate immune
response. Here we report that in vitro treatment of monocytes with
IL-28 or IL-29 did not interfere with the capacity of IL-4+GM-
CSF to induce their differentiation into DCs, based on similar high
CD80, CD86 and low CD14 levels (Table 2). In contrast, the
presence of IL-28A, IL-29, or their combination, lead to
from blood (A,B) and liver RNA (C–E) were paired for HCV and SVR. (F) IFN-lR1 expression was analyzed in various cell types of PBMCs by flow
cytometry using isotype or IFN-lR1 fluorescent antibody. Representative histogram of n = 4 is shown. * indicates p,0.05 compared to controls.
doi:10.1371/journal.pone.0044915.g001
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Figure 2. IFN-l influences the DCs phenotype and functional capacity. Monocyte-derived DCs from healthy individuals were generated
without (control) or with a combination of IL-29 and IL-28A (control+IFN-l), or from patients with chronic HCV (HCV+IFN-l) or recovered HCV
infection (SVR+IFN-l) for 7 days, after which they were included in a mixed lymphocyte reaction (MLR) with allogeneic CD4+ T cells for 4 days.
Incorporation of 3H-Td during the last 16 hours of MLR, read as counts per minute (cpm), was considered indicative of the stimulatory capacity of DCs
(A, left). DCs of controls, HCV and SVR individuals were analyzed as above (A, right). Control DCs, DCs generated for 7 days with IFN-l, and DCs
IL-28 and IL-29 Modulate Dendritic Cells
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development of DCs with decreased T cell stimulatory capacity
(Fig. 2A left). To this end, IFN- l-exposed DCs of healthy
individuals were similar to primary DCs of cHCV patients (Fig. 2A
right). We further identified that IFN- l treatment was inhibitory
for DCs of SVR individuals similar to healthy individuals (Fig. 2A
right). Importantly, IFN- l did not further suppress or restore the
already impaired stimulatory capacity of cHCV-DCs (Fig. 2A
right). The presence of IFN- l for the entire duration of DC
generation was necessary to establish the development of
inhibitory DCs; limited exposure to IFN- l at the end of DC
generation did not affect the stimulatory properties of DCs
(Fig. 2B). Exposure of monocytes to anti-IFN- lR siRNA, but not
to non-specific scrambled siRNA, caused down-regulation of IFN-
lR expression (Fig. 2C). More importantly, anti-IFN- lR siRNA-
treated monocytes which had differentiated to DCs in the presence
of IFN- l were protected from the IFN- l treatment-induced
inhibitory phenotype of DCs, as indicated directly by lack of
functional inhibitory activity of these DCs (Fig. 2D) and indirectly
by the corresponding lack of FoxP3 increase in mixed lymphocyte
reaction (MLR) (Fig. 2E). These data suggested that the effect of
IFN- l treatment on DCs is IFN- lR-dependent. In contrast, pre-
exposure of T cells to IFN- l prior to their contact with DCs did
not affect their proliferation if IFN- l-naı¨ve control DCs were used
as stimulators in IFN- l-free co-culture conditions (Fig. 2F).
Collectively, these data suggested that treatment with IFN- l is
inhibitory for DC function via IFN- lR on DCs.
IFN-l-exposed DCs Exhibit PD-1/PD-L1-dependent
Regulatory Capacity
The stimulatory capacity of DCs is highly dependent on their
cytokine and surface molecule profiles. HCV DCs triggered lower
levels of IL-2 (Fig. 3A) and IL-12 (Fig. 3B) compared to control
and SVR DCs in MLR. IL-2 (Fig. 3A) and IL-12 (Fig. 3B) levels
were also decreased during MLRs with IFN- l-exposed DCs when
DCs originated from controls or SVR. Exposures of HCV DCs to
IFN- l lead to further inhibition of IL-12 but not IL-2 production
(Fig. 3A&B). Neutralization of inhibitory factors (PD-1), or
supplementation with stimulatory factors (IL-12 or IL-2), restored
the stimulatory capacity of IFN-l treated DC (Fig. 3C); neutral-
ization of IL-10 had only minimal effects. We further identified
increased levels of PD-L1 (Fig. 3D,F left) and PD-1 (Fig. 3E,F
right) RNA (Fig. 3D,E) and protein (Fig. 3F) in MLRs with IFN-l-
treated DCs. These data suggested that IFN- l-treated DCs
created a regulatory environment that impairs T cell activation.
IFN- l-treated DCs Promote Proliferation of Regulatory T
Cells
An environment with decreased IL-12 levels and increased
expression of negative co-stimulatory molecules, such as PD-1/
PD-L1 system, often leads to skewed composition of proliferating
T cells. We found preferential proliferation of CD4+CD25+ cells in
IFN- l-DC/T cells, indicated by higher frequency of CFSElow
cells, compared to control DC/T cells co-cultures (Fig. 4A). The
proliferation of CD4+CD252 exposed to IFN- l DCs was
reduced, suggested by lower frequency of CFSElow cells compared
to control DCs in a MLR (Fig. 4B). We further identified increased
expression of FoxP3 RNA levels (Fig. 4C) and higher frequency of
FoxP3+ Tregs (Fig. 4D) in IFN- l-DC/T cells compared to control
DC/T cells co-cultures. These data suggested that IFN- l-DCs
favor proliferation of FoxP3+ T cells.
Tregs are very efficient in suppressing effector T cells. When
present in comparable numbers, IFN- l-DC-expanded Tregs have
a comparable inhibitory capacity to Tregs previously exposed to
control DCs (Fig. 4E). Further, IFN- l-DC-expanded Tregs
produce IL-10 and express CD45RA but not in excessive amounts
compared to control cells (Fig. S3). These data suggested that the
inhibitory effects of IFN- l-DCs are likely due to their capacity to
increase the numbers of Tregs via DC-dependent proliferation;
their ability to induce Tregs with more powerful regulatory
functions is unlikely.
IFN- l-DCs Promote Expansion of Pre-existing but not de
novo Generation of Tregs
Finally, we addressed the origin of proliferating Tregs upon co-
culture with IFN- l-DCs. The frequency of FoxP3+ regulatory T
cells (Fig. 4F) was increased upon T cell co-culture with IFN- l-
DCs when T cell population contained both CD4+CD25+ and
CD4+CD252 T cells. In contrast, no additional FoxP3-bearing
cells were generated upon co-culture of IFN- l-DCs with
CD4+CD252 lymphocytes (Fig. 4F). These results suggested that
IFN- l-DCs promote expansion of pre-existing, but not de novo
generation of FoxP3+ T cells.
Discussion
Although type III IFNs are currently in clinical trials as potential
therapeutic agents to eradicate HCV infection, their mechanisms
of action are not fully understood. Here we report that IFN- l
expression is increased in cHCV patients, both in blood and liver.
Our results provide novel evidence for the immunomodulatory
exposed to IFN-l only during the last 24 hrs on day 6, were included in MLR. Incorporation of 3H-Td during the last 16 hours of MLR, read as cpm, was
considered indicative of stimulatory capacity of DCs (B). Normal monocytes were transfected with scrambled or IFN-lR-specific siRNA and analyzed
for the content of IFN-lR-coding RNA 72 hours later by RT-qPCR, as described in Methods. Fold change compared to mock-transfected cells was
calculated from n = 3 sets of experiments (C). Normal monocytes were transfected as above, exposed to IL-4+GM-CSF in the presence or absence of
IFN-l for 7 days and included in MLR with normal T cells. T cells alone and DCs alone were used as controls of non-specific proliferation. Incorporation
of 3H-Td during the last 16 hours of MLR, read as cpm, was measured as indicative of stimulatory capacity of DCs from n = 5 (D). Total RNA was
extracted from MLR co-cultures corresponding to those described in panel D and the content of FoxP3-coding mRNA was analyzed using RT-qPCR, as
described in methods. Fold change compared to scrambled MLR which used siRNA-exposed DCs as control was calculated from n = 5 sets of
experiments (E). T cells of control healthy individuals were treated with IFN-l for 5 days, after which they were washed extensively and co-cultured in
MLR with dendritic cells which were generated with IL-4+GM-CSF without IFN-l (IFN-l-naı¨ve) for 4 days. There was no IFN-l present during MLR.
Incorporation of 3H-Td during the last 16 hours of MLR, read as cpm, was measured as indicative of stimulatory capacity of DCs from n = 5 sets of
experiments (F). * indicates p,0.05 compared to controls.
doi:10.1371/journal.pone.0044915.g002
Table 2. Phenotypic analyses of DCs generated in the
presence or absence of IFN-l.
Marker Control DCs IFN-l-exposed DCs
CD80 MFI 4656212 4886156
CD86 MFI 214646 209684
CD14 MFI 1266101 131666
doi:10.1371/journal.pone.0044915.t002
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action of IFN- l in anti-HCV immunity and add new complexity
to the understanding of the anti-HCV potential of IFN- l.
We found elevated levels of serum IFN- l upon cHCV; these
data are in agreement with some [19] but not other [20] recent
Figure 3. IFN-l treatment-induced inhibitory DCs phenotype is dependent on IL-10 and PD-1/PD-L1 ligand. Monocyte-derived DCs
from healthy individuals were generated without (control) or with IFN-l (combination of IL-29 and IL-28A, called IFN-l-DC) for 7 days, after which
they were included in the mixed lymphocyte reaction (MLR) with allogeneic CD4+ T cells for 4 days. Co-culture supernatants from indicated groups
were analyzed for IL-2 (A), IL-12 (B) by ELISA; mean6SD pg/ml shown. Neutralizing a-IL-10 or a-PD-1 antibodies, or recombinant (r) IL-2 or IL-12 were
added during MLR and T cell proliferation was analyzed as described in Methods; shown mean6SD cpm from n = 5 sets of experiments (C). Entire
MLR co-culture was analyzed for PD-L1(D) or PD-1 (E) mRNA. DCs were analyzed for PD-L1 expression by flow cytometry using isotype or specific
fluorescent antibodies (MFI control 4146126 vs 622698 IFN- l DCs) (F, left). T cells from MLR co-culture cells were analyzed for PD-1 expression by
flow cytometry using isotype or specific fluorescent antibodies (MFI control 125627 vs 187639 IFN- l DCs) (F, right). * indicates p,0.05 compared to
controls.
doi:10.1371/journal.pone.0044915.g003
IL-28 and IL-29 Modulate Dendritic Cells
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Figure 4. IFN-l-DCs promote proliferation of existing but not de novo generation of regulatory T cells. (A,B) CD4+ T cells were labeled
with CFSE and cultured alone (red) or co-cultured with control (blue) or IFN-l-DCs (green); at the end of culture CD4+CD25+ cells (A) or CD4+CD252
cells (B) were analyzed for CFSE content by flow cytometry; representative histogram of n = 8 is shown. (C,D) The DC/T cells co-culture was analyzed
for FoxP3 mRNA (C) using specific primers in quantitative PCR or for the frequency of FoxP3+ cells by flow cytometry (D); data are shown as fold
change compared to control DC/T cells co-culture (C) or as representative flow cytometry dot blots (D). (E) T cells were included into 2 rounds of MLR.
The first MLR was set up as described in Fig. 3 with CD4+ T cells as responders and control or IFN- l-exposed DCs as stimulators. At the end of this first
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studies. We further provide novel data that, in contrast to patients
with active HCV infection, serum levels of IFN- l in individuals
with HCV SVR were comparable to HCV-naı¨ve control. These
data indicate that HCV presence is needed for increased IFN- l
production; similar findings were reported in other hepatotropic
viral infections including HBV and and HIV [21,22] infections.
This was further supported by our observation, also confirmed by
Diegelmann et al [19], that the presence of liver inflammation due
to metabolic disturbances (such as in non-alcoholic steatohepatitis)
did not lead to increased serum levels of IFN- l.
We also found robust expression of the IFN- l receptor (IFN-
lR) in dendritic cells and to a lesser extent in T cell populations.
We observed expression of the other component of the IFN- lR,
IL-10R2, which is also shared between IL-10 and IL-22 [8]. While
increased levels of IL-10 have been reported in HCV infection, to
date there is no evidence for IL-10 modulating IFN- lR function.
Our finding of the inhibitory effect of IFN-l on dendritic cells
indicates that distribution of IFN- lR may influence tissue-specific
effects of IFN- l during HCV infection.
HCV is difficult to eradicate and this could be related to its
prolific capacity to manipulate the immune system. Here we
showed that IFN- l acts as a modulator of immune responses
during HCV infection in three inter-related areas described below.
First, we demonstrated that IFN- l directs DCs to a regulatory
phenotype with increased expression of negative regulatory
molecules. The IFN- l-exposed DCs exhibited diminished
capacity to stimulate T cell proliferation in a PD-1/PD-L1
dependent manner with contribution from the imbalanced
cytokine milieu, such as low IL-12 and IL-2 and/or high IL-10
production. In fact, the functional potential of the IFN- l-
generated DCs, shown here, closely resembles the functional
deficits seen in myeloid dendritic cells of HCV patients, as
previously reported by our group, and others, although these
changes were not identified in other patient cohorts (reviewed in
[11,15]). A limitation of our study is that monocyte-derived DCs
may not fully represent the in vivo DC life cycle. However, our data
suggest a PD-1/PD-L1-dependent effect of IFN- l on the
stimulatory capacity of DCs. We observed comparable effects of
a PD-1 antibody on control DCs that express less PD-L1 levels
thus lending support to a combinatory defect, including, but most
likely not limited to, negative co-stimulatory receptors and
cytokines. Nevertheless, the newly-discovered inhibitory effects of
IFN-l on DCs in our study are not surprising, taking into account
the functional redundancy between IFN- l and IFN-a and
impaired DC response to IFN-a in patients with HCV infection
[23].
Second, we show that IFN- l-exposed DCs are potent triggers
involved in the proliferation of Tregs. We and others reported
increased frequency of Tregs upon HCV infection [12–14,18].
Here we observed that IFN- l-treated DCs trigger the prolifer-
ation of pre-existing Tregs and failed to induce de novo Treg
generation.
Third, we found that the Tregs expanded in the presence of
IFN- l-DC have preserved their inhibitory capacity in a new
MLR. These characteristics of the IFN- l-DC-expanded Tregs
closely resemble findings in primary CD4+CD25+FoxP3+ Tregs
of HCV patients [12–15,18,24].
Finally, in light of the fact that IFN-ls induce a subset of ISGs
stimulated by Type I IFNs and not a unique subset of genes [25],
our novel finding of the immunomodulatory effects of IFN-l on
DCs require further investigations. Further studies will be needed
to identify whether the immunomodulatory effect of IFN-l on the
MDCs/Tregs system may constitute a desirable anti-inflammatory
potential, in parallel or in addition to its previously-reported direct
anti-viral effects of IFN-l against HCV [4,5]. Alternatively, IFN-l
may play have a detrimental role due, at least in part, to its role in
Tregs expansion.
In conclusion, we found increased levels of IFN-l, IL-28, and
IL-29 in serum and increased expression of these cytokines and
their receptor in the liver during chronic HCV infection. We also
identified the functional effect of IFN- l on DCs, which results in
dendritic cell-dependent expansion of regulatory T cells. Our
study suggests that the immunomodulatory effects of IFN- l on
DC and T cell populations will need to be considered in future
clinical studies involving IFN- l therapy in HCV infection.
Supporting Information
Figure S1 Differential expression of IFN- lR in various
cell types of PBMCs. PBMCs or indicated immune cell
populations, purified as described in Methods, were analyzed for
listed genes using qPCR and specific primers; the amplified
products were separated in agarose gel and representative blots
from one representative individual are shown.
(TIF)
Figure S2 cHCV patients have increased levels of FoxP3
and reduced BDCA-2 in PBMCs compared to controls.
Cell populations were isolated based on specific markers, as
described in methods. Equal amounts of total cellular RNA was
transcribed to DNA and analyzed for expression of specific
markers by qPCR using SYBRgreen and specific primers. (A)
PCR cycles, adjusted to housekeeping 18S control, are shown as
mean 6SD. (B) The mean RNA levels of specific markers (FoxP3-
top, BDCA-2-bottom) in PBMCs of controls were considered as
equal to 1 and the fold change in HCV patient groups compared
to controls was calculated (shown as mean6SD fold). * indicates
p,0.05.
(TIF)
Figure S3 Tregs expanded by IFN- l-exposed DCs have
a regulatory phenotype. T cells were co-cultured with either
control or IFN- l-exposed DCs for 10 days, after which they were
stimulated with PMA+Ionomycin for 4 hrs in the presence of
GolgiStop. Cells were permeabilized, stained with specific
antibodies, fixed, and analyzed by flow cytometry. Tregs were
identified as CD4+CD25+FoxP3+ and analyzed for expression of
CD45RA and IL-10 as indicated. Representative histograms of
n = 5 are shown.
(TIF)
Table S1 Primers for PCR analyses.
(DOC)
MLR, the T cells were purified into CD4+CD252 and CD4+CD25+ populations using magnetic beads and equal numbers of cell types were included
into a second round MLR with allogeneic normal DCs at indicated DC/T cell ratio. Proliferation during the second MLR was assessed by 3H-Td
incorporation during the final 16 h of the 5-day co-culture. Mean6SD cpm values from n = 8 are shown. (F) IFN- l-exposed DCs were co-cultured with
CD4+ (including CD25+ and CD25- populations) or CD4+CD252 or CD4+CD25+ T cells; T cell cultures without DCs were used as controls. The co-
cultures were analyzed by flow cytometry for the frequency of FoxP3+ cells (F). Representative set of flow cytometry dotblots of n = 4 with similar
results is shown. * indicates p,0.05 compared to controls.
doi:10.1371/journal.pone.0044915.g004
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